Masaya Miyazaki1, Kenichi Saito2, Takashi Yanagawa2, Hirotaka Chikuda2, Yoshito Tsushima3. 1. Department of Interventional Radiology and Clinical Ultrasound Center, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan. mmiyazak@gunma-u.ac.jp. 2. Department of Orthopedic Surgery, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan. 3. Department of Interventional Radiology and Clinical Ultrasound Center, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Abstract
PURPOSE: This prospective phase I trial was conducted to evaluate the safety of percutaneous cryoablation for osteoid osteoma (OO). MATERIALS AND METHODS: Nine patients with OO (mean tumor size: 5.9 mm; tibia, n = 5; femur, n = 2; lumbar spine, n = 2) were enrolled and treated with percutaneous cryoablation. The primary endpoint was the evaluation of the treatment safety as determined using step-by-step registration. The secondary endpoints were the incidence and grade of adverse events by CTCAE version 4.0, and the short-term efficacy of this treatment. Based on a decrease in the numerical rating scale (NRS) score, efficacy was classified as significantly effective (SE ≥ 5 or reached 0-2), moderately effective (ME 2-4), or not effective (NE < 2 or increase). RESULTS: Cryoablation procedures were completed in all patients. Major adverse events (≥ grade 3) related to the procedure were not observed. Minor adverse events (≤ grade2) were observed in 22-67%. The mean NRS score was 7 before treatment, 0.6 at 4-week, 0.1 at 6-month, and 0 at 1-year post-treatment. All procedures were classified as SE. CONCLUSION: Percutaneous cryoablation is a safe treatment for OO. Future phase II trials with large patient cohorts are warranted.
PURPOSE: This prospective phase I trial was conducted to evaluate the safety of percutaneous cryoablation for osteoid osteoma (OO). MATERIALS AND METHODS: Nine patients with OO (mean tumor size: 5.9 mm; tibia, n = 5; femur, n = 2; lumbar spine, n = 2) were enrolled and treated with percutaneous cryoablation. The primary endpoint was the evaluation of the treatment safety as determined using step-by-step registration. The secondary endpoints were the incidence and grade of adverse events by CTCAE version 4.0, and the short-term efficacy of this treatment. Based on a decrease in the numerical rating scale (NRS) score, efficacy was classified as significantly effective (SE ≥ 5 or reached 0-2), moderately effective (ME 2-4), or not effective (NE < 2 or increase). RESULTS: Cryoablation procedures were completed in all patients. Major adverse events (≥ grade 3) related to the procedure were not observed. Minor adverse events (≤ grade2) were observed in 22-67%. The mean NRS score was 7 before treatment, 0.6 at 4-week, 0.1 at 6-month, and 0 at 1-year post-treatment. All procedures were classified as SE. CONCLUSION: Percutaneous cryoablation is a safe treatment for OO. Future phase II trials with large patient cohorts are warranted.
Authors: Tyler M Coupal; Paul I Mallinson; Peter L Munk; David Liu; Paul Clarkson; Hugue Ouellette Journal: AJR Am J Roentgenol Date: 2014-05 Impact factor: 3.959
Authors: Ralf-Thorsten Hoffmann; Tobias F Jakobs; Constanze H Kubisch; Christoph G Trumm; Christof Weber; Hans-Roland Duerr; Thomas K Helmberger; Maximilian F Reiser Journal: Eur J Radiol Date: 2009-01-13 Impact factor: 3.528
Authors: Matthew R Callstrom; Damian E Dupuy; Stephen B Solomon; Robert A Beres; Peter J Littrup; Kirkland W Davis; Ricardo Paz-Fumagalli; Cheryl Hoffman; Thomas D Atwell; J William Charboneau; Grant D Schmit; Matthew P Goetz; Joseph Rubin; Kathy J Brown; Paul J Novotny; Jeff A Sloan Journal: Cancer Date: 2012-10-12 Impact factor: 6.860
Authors: Daniel I Rosenthal; Francis J Hornicek; Martin Torriani; Mark C Gebhardt; Henry J Mankin Journal: Radiology Date: 2003-08-27 Impact factor: 11.105
Authors: D I Rosenthal; F J Hornicek; M W Wolfe; L C Jennings; M C Gebhardt; H J Mankin Journal: J Bone Joint Surg Am Date: 1998-06 Impact factor: 5.284
Authors: Roberto Fiori; Marco Forcina; Carlo Di Donna; Adolfo D'Onofrio; Luigi Spiritigliozzi; Armando Ugo Cavallo; Roberto Floris Journal: Radiol Case Rep Date: 2019-06-06